Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Graphite Bio
About
Graphite Bio is a next-generation gene editing company that is driven to apply our breakthrough technology.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $150.74M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2020
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 15, 2021 | Series B | $150.74M | 1 | — | — | Detail |
| Sep 16, 2020 | Series A | $45M | 1 |
Versant Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
— | Series B |
